Search Result

Results for "

lupus erythematosus

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AIM2 (2) Amyloid-β (1) Apoptosis (8) Autophagy (7) Btk (4) c-Fms (1) C-type Lectin-like Receptors (CTLRs) (1) CD19 (1) CD20 (1) CD28 (1) Chemerin Receptor (1) Complement System (1) CXCR (1) Cytochrome P450 (1) DNA/RNA Synthesis (1) Drug Isomer (1) Endogenous Metabolite (4) Fc Receptor (FcR) (1) Glucocorticoid Receptor (5) IFNAR (5) Interleukin Related (3) IRAK (1) Isotope-Labeled Compounds (4) JAK (2) Mitochondrial Metabolism (1) NF-κB (2) p38 MAPK (1) Parasite (5) Potassium Channel (6) PROTACs (1) Protein Arginine Deiminase (1) ROS Kinase (3) SARS-CoV (5) STAT (1) TNF Receptor (7) Toll-like Receptor (TLR) (10) Transmembrane Glycoprotein (2)
By Research Areas:	Cancer (15) Cardiovascular Disease (3) Endocrinology (6) Infection (5) Inflammation/Immunology (58) Metabolic Disease (7)
Oligonucleotides:	CpG ODNs (4)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99842A

Dapirolizumab	TNF Receptor	Inflammation/Immunology
Dapirolizumab is a monoclonal antibodi against CD40 ligand. Dapirolizumab targets CD40L, blocks its interaction with CD40 receptors, and inhibits adaptive immune activation. Dapirolizumab attenuates systemic lupus erythematosus .

HY-B0214

Prednisone 5+ Cited Publications Dehydrocortisone	Glucocorticoid Receptor Apoptosis	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Prednisone (Adasone) is a corticosteroid agent with anti-inflammatory and immunosuppressive effects that can be used to study diseases related to systemic lupus erythematosus .

HY-147264

Edecesertib GS-5718	IRAK	Inflammation/Immunology
Edecesertib (GS-5718) is a selective, potent, orally active IRAK-4 inhibitor. Edecesertib has anti-inflammatory activity. Edecesertib can be used for rheumatoid arthritis (RA) and lupus erythematosus (LE) research .

HY-145588

Povorcitinib INCB54707	JAK	Inflammation/Immunology
Povorcitinib (INCB54707) is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib is used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP) .

HY-15374

Frentizole	Amyloid-β	Inflammation/Immunology
Frentizole, an FDA-approved immunosuppressant, is a Aβ-ABAD (binding alcohol dehydrogenase) interaction inhibitor with an IC₅₀ value of 200 μM. Frentizole is used in studies of diseases related to rheumatoid arthritis and systemic lupus erythematosus .

HY-P99219

Sifalimumab MEDI-545; MDX 1103	IFNAR	Inflammation/Immunology
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research .

HY-B0214S2

Prednisone-d4 Dehydrocortisone-d4	Apoptosis Glucocorticoid Receptor Isotope-Labeled Compounds	Inflammation/Immunology Endocrinology Cancer
Prednisone-d₄ is deuterated labeled Prednisone (HY-B0214). Prednisone (Adasone) is a corticosteroid agent with anti-inflammatory and immunosuppressive effects that can be used to study diseases related to systemic lupus erythematosus .

HY-113986B

(S)-Dexfadrostat (S)-Fadrozole; (S)-CGS 16949A free base; (S)-FAD286	Cytochrome P450	Inflammation/Immunology Endocrinology Cancer
(S)-Dexfadrostat ((S)-Fadrozole) is an aromatase inhibitor with an IC₅₀ of 4.6 nM in human placental microsomes in vitro. (S)-Dexfadrostat can be used in the study of estrogen-dependent breast cancer, gynecomastia, and systemic lupus erythematosus .

HY-172374

KV1.3-IN-2	Potassium Channel	Inflammation/Immunology
KV1.3-IN-2 (Compound I) inhibits kv1.3 potassium channel without affecting hERG channel. KV1.3-IN-2 can be used in research of immune-related diseases such as psoriasis, rheumatoid arthritis, and systemic lupus erythematosus .

HY-P991313

PD-360324	c-Fms	Inflammation/Immunology
PD-360324 is a human monoclonal antibody (mAb) targeting CSF1/M-CSF. PD-360324 can be used in cutaneous lupus erythematosus, pulmonary sarcoidosis and rheumatoid arthritis research .

HY-W031727

Hydroxychloroquine Maximum Cited Publications 62 Publications Verification	Parasite Toll-like Receptor (TLR) SARS-CoV Autophagy	Infection Cancer
Hydroxychloroquine (HCQ) is a synthetic oral antimalarial drug that can be used in the study of malaria and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Hydroxychloroquine is a potent autophagic flux inhibitor with antiviral activity (such as SARS-CoV-2 virus) that inhibits Toll-like receptor 7/9 (TLR7/9) signaling .

HY-145588A

Povorcitinib phosphate INCB54707 phosphate	JAK	Inflammation/Immunology
Povorcitinib (INCB54707) phosphate is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib phosphate can be used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP) (information extracted from patent WO2021076124A1) .

HY-153460

TLR7/8/9 antagonist 2	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7/8/9 antagonist 2 is an orally active TLR7/8/9 antagonist. TLR7/8/9 antagonist 2 has inhibitory activities for HEK/hTLR7, HEK/hTLR8 and HEK/hTLR9 with IC₅₀ values of 0.011 μM, 0.029 μM and 0,052 μM, respectively.TLR7/8/9 antagonist 2 has high bioavailability in vivo.TLR7/8/9 antagonist 2 can be used for the research of auto-inflammatory diseases such as systemic lupus erythematosus or lupus nephritis .

HY-109143B

(R)-Elsubrutinib (R)-ABBV-105	Btk	Inflammation/Immunology Cancer
(R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor. (R)-Elsubrutinib can be used in studies of immune diseases (such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, systemic lupus erythematosus) and cancer .

HY-136093B

Lixumistat IM156 free base; HL156A free base; HL271 free base	Mitochondrial Metabolism	Cancer
Lixumistat (IM156) is a novel biguanide mitochondrial protein complex 1 inhibitor of oxidative phosphorylation (OXPHOS) with anti-tumor activity. Lixumistat regulates OXPHOS to attenuate mitochondrial metabolic reprogramming and inhibit lung fibrosis. Lixumistat also suppresses B-cell activation to alleviate systemic lupus erythematosus .

HY-144619

TLR7/8 antagonist 2	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7/8 antagonist 2 (Compound 15) is a potent and orally active agonist of TLR7/8 with IC₅₀s of 4.9 and 0.6 nM, respectively. Inappropriate activation of TLR7 and TLR8 is linked to several autoimmune diseases, such as lupus erythematosus. TLR7/8 antagonist 2 has the potential for the research of autoimmune diseases .

HY-P99168

Anifrolumab 2 Publications Verification	IFNAR	Inflammation/Immunology
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research .

HY-P3560

Edratide TV 4710	Apoptosis	Inflammation/Immunology
Edratide (TV 4710) is a synthetic peptide of 19 amino acid based on the complementarity-determining region 1 (CDR1) of a human anti-DNA antibody that expresses a major idiotype denoted 16/6 Id. Edratide reduces the rates of apoptosis (Apoptosis) and down-regulates of caspase-8 and caspase-3, up-regulates Bcl-xL. Edratide has the potential for the research of systemic lupus erythematosus (SLE) .

HY-148411

Abetimus LJP 394 free base	DNA/RNA Synthesis	Inflammation/Immunology
Abetimus (LJP 394 free base) is an immunosuppressant consisting of four double-stranded DNA (dsDNA) oligonucleotides. Abetimus is capable of crosslinking anti-dsDNA antibodies on the surface of B cells, and decreases anti-dsDNA antibodies levels. Abetimus has the potential for research of systemic lupus erythematosus .

HY-P99220

Tabalumab LY2127399	TNF Receptor	Inflammation/Immunology Cancer
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .

HY-P3507

Dalazatide ShK-186	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-162649

TIC10g	Toll-like Receptor (TLR) NF-κB p38 MAPK	Inflammation/Immunology
TIC10g is a dual inhibitor for toll-like receptor 7 and 9 (TLR7 and TLR9), which inhibits TLR7 and TLR9 mediated TNF-α release in mouse macrophages (IC₅₀ is 14.5 μM and 6.5 μM) and human B lymphocytes (IC₅₀ is 7.69 μM and 11.5 μM). TIC10g inhibits the activation of NF-κB and MAPK, and exhibits anti-inflammatory activity against systemic lupus erythematosus and rheumatoid arthritis .

HY-P3507A

Dalazatide TFA ShK-186 TFA	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-139567

Afimetoran BMS-986256	Toll-like Receptor (TLR) NF-κB Apoptosis	Inflammation/Immunology
Afimetoran (BMS-986256) is an orally active, selective, and highly bioavailable TLR7/8 antagonist. Afimetoran (BMS-986256) can inhibit TLR7/8 activation of the NF-κB pathway and reverse TLR7 mediated resistance to steroid induced apoptosis in plasma cell like dendritic cells (pDCs). Afimetoran (BMS-986256) can be used for research on inflammation and autoimmune diseases (systemic lupus erythematosus) .

HY-150751

ODN TTAGGG 1 Publications Verification ODN A151	Toll-like Receptor (TLR) AIM2	Inflammation/Immunology
ODN TTAGGG (A151), inhibitory oligonucleotide (ODN), is a TLR9, AIM2 and cGAS antagonist. ODN TTAGGG is immunosuppressive and inhibits AIM2 inflammasome activation, as well as cGAS activation, by competing with DNA. ODN TTAGGG can be used in the study of lupus erythematosus and other related autoimmune diseases. ODN TTAGGG sequence: 5'-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-3' .

HY-150751C

ODN TTAGGG sodium 1 Publications Verification ODN A151 sodium	AIM2 Toll-like Receptor (TLR)	Inflammation/Immunology
ODN TTAGGG sodium, inhibitory oligonucleotide (ODN), is a TLR9, AIM2 and cGAS antagonist. ODN TTAGGG sodium is immunosuppressive and inhibits AIM2 inflammasome activation, as well as cGAS activation, by competing with DNA. ODN TTAGGG sodium can be used in the study of lupus erythematosus and other related autoimmune diseases. ODN TTAGGG sequence: 5'-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-3' .

HY-P99761

Obexelimab XmAb5871	CD19 Apoptosis	Inflammation/Immunology
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .

HY-105037

Forigerimod IPP-201101	Autophagy	Inflammation/Immunology
Forigerimod (IPP-201101) is a CD4 T-cell modulator. Forigerimod is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-P99893

Rozibafusp alfa AMG-570	CD28 TNF Receptor	Others
Rozibafusp alfa (AMG-570) is a humanized IgG2-κ monoclonal antibody targets ICOSL and BAFF. Prezalumab demonstrates beneficial activities on the arthritis of systemic lupus erythematosus. Prezalumab can be used for the research of sjogren's syndrome cutaneous lupus erythematosus, psoriasis and systemic lupus erythematosus (SLE) .

HY-105037A

Forigerimod TFA IPP-201101 TFA	Autophagy	Inflammation/Immunology
Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-P99315

Ruplizumab BG 9588; Anti-Human CD40L Recombinant Antibody; Hu5c8	TNF Receptor	Inflammation/Immunology
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-115676

GSK199 analog hydrochloride	Protein Arginine Deiminase	Inflammation/Immunology
GSK199 analog hydrochloride belongs to a class of compounds that inhibit PAD4 (guanidinoarginine deiminase 4). GSK199 analog hydrochloride has potential uses in diseases including rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, and psoriasis .

HY-P99625

Frexalimab SAR441344; INX-021	TNF Receptor	Metabolic Disease Inflammation/Immunology
Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sj gren’s syndrome and type I diabetes research .

HY-76082A

L-Pyroglutamic acid sodium	Endogenous Metabolite	Inflammation/Immunology
L-Pyroglutamic acid sodium is the levo-isomer of Pyroglutamic acid. L-Pyroglutamic acid sodium is the biologically active enantiomer in humans. Pyroglutamic acid is an intermediate in glutathione metabolism. L-Pyroglutamic acid sodium can be used as a biomarker for systemic lupus erythematosus (SLE) .

HY-76082

L-Pyroglutamic acid 2 Publications Verification	Endogenous Metabolite	Inflammation/Immunology
L-Pyroglutamic acid is the levo-isomer of Pyroglutamic acid. L-Pyroglutamic acid is the biologically active enantiomer in humans. Pyroglutamic acid is an intermediate in glutathione metabolism. L-Pyroglutamic acid can be used as a biomarker for systemic lupus erythematosus (SLE) .

HY-B0214R

Prednisone (Standard) Dehydrocortisone (Standard)	Glucocorticoid Receptor Apoptosis	Inflammation/Immunology Endocrinology Cancer
Prednisone (Standard) is the analytical standard of Prednisone. This product is intended for research and analytical applications. Prednisone (Adasone) is a corticosteroid agent with anti-inflammatory and immunosuppressive effects that can be used to study diseases related to systemic lupus erythematosus .

HY-B0214S1

Prednisone-d7 Dehydrocortisone-d₇	Isotope-Labeled Compounds Apoptosis Glucocorticoid Receptor	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Prednisone-d₇ (Dehydrocortisone-d₇) is deuterium labeled Prednisone. Prednisone (Adasone) is a corticosteroid agent with anti-inflammatory and immunosuppressive effects that can be used to study diseases related to systemic lupus erythematosus .

HY-P991272

ATR-107	Interleukin Related	Inflammation/Immunology
ATR-107 is a humanized monoclonal antibody inhibitor targeting interleukin-21 receptor (IL-21R). ATR-107 is promising for research of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus .

HY-18018

RN486 3 Publications Verification	Btk	Inflammation/Immunology
RN486 is a potent, selective and orally active Btk inhibitor with an IC₅₀ of 4.0 nM and a K_d of 0.31 nM. RN486 is less active for other kinases. RN486 can be used for rheumatoid arthritis and systemic lupus erythematosus research .

HY-P9990

Litifilimab BIIB059	C-type Lectin-like Receptors (CTLRs) Transmembrane Glycoprotein	Inflammation/Immunology
Litifilimab (BIIB059) is a humanized anti-BDCA2 IgG1 monoclonal antibody administered subcutaneously. Litifilimab can inhibit the production of type I interferons, cytokines and chemokines. Litifilimab can be used in the research of diseases such as systemic lupus erythematosus .

HY-P991251

QX006N	IFNAR	Inflammation/Immunology
QX006N is a humanized monoclonal antibody inhibitor targeting human interferon α/β receptor 1 (IFNAR1). QX006N is promising for research of systemic lupus erythematosus (SLE) and other IFNAR1-related autoimmune diseases .

HY-P9952

Belimumab 2 Publications Verification LymphoStat B	TNF Receptor CD20	Inflammation/Immunology Cancer
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research .

HY-17437A

Mefloquine hydrochloride 3 Publications Verification Mefloquin hydrochloride	Parasite SARS-CoV Autophagy Potassium Channel ROS Kinase	Infection Metabolic Disease Inflammation/Immunology Cancer
Mefloquine hydrochloride (Mefloquin hydrochloride), a quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine hydrochloride is also a K ⁺ channel (KvQT1/minK) antagonist with an IC₅₀ of ~1 μM. Mefloquine hydrochloride can be used for malaria, systemic lupus erythematosus and cancer research .

HY-150740A

ODN 21595 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 21595 sodium is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 sodium inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 sodium reduces the expression of CD86 and HLA-DR. ODN 21595 sodium has the potential for the research of systemic lupus erythematosus (SLE) .

HY-150740

ODN 21595	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 21595 is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 reduces the expression of CD86 and HLA-DR. ODN 21595 has the potential for the research of systemic lupus erythematosus (SLE) .

HY-150095

YE6144 1 Publications Verification	IFNAR	Inflammation/Immunology
YE6144 is a prototypical interferon regulatory factor 5 (IRF5) inhibitor. YE6144 selectively suppresses IRF5 activity through inhibition of IRF5 phosphorylation .

HY-17437

Mefloquine 3 Publications Verification Mefloquin	Parasite Autophagy SARS-CoV Potassium Channel ROS Kinase	Infection Metabolic Disease Inflammation/Immunology Cancer
Mefloquine (Mefloquin), an orally active and potent quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K ⁺ channel (KvQT1/minK) antagonist with an IC₅₀ of ~1 μM. Mefloquine can be used for malaria, systemic lupus erythematosus and cancer research .

HY-76082R

L-Pyroglutamic acid (Standard)	Endogenous Metabolite	Inflammation/Immunology
L-Pyroglutamic acid (Standard) is the analytical standard of L-Pyroglutamic acid (HY-76082). This product is intended for research and analytical applications. L-Pyroglutamic acid is the levo-isomer of Pyroglutamic acid. L-Pyroglutamic acid is the biologically active enantiomer in humans. Pyroglutamic acid is an intermediate in glutathione metabolism. L-Pyroglutamic acid standard can be used as a biomarker for systemic lupus erythematosus (SLE) .

HY-76082S1

L-Pyroglutamic acid-13C5	Isotope-Labeled Compounds Endogenous Metabolite	Inflammation/Immunology
L-Pyroglutamic acid- ¹³C₅ is the ¹³C labeled L-Pyroglutamic acid (HY-76082) . L-Pyroglutamic acid is the levo-isomer of Pyroglutamic acid. L-Pyroglutamic acid is the levo-isomer of Pyroglutamic acid. L-Pyroglutamic acid is the biologically active enantiomer in humans. Pyroglutamic acid is an intermediate in glutathione metabolism. L-Pyroglutamic acid can be used as a biomarker for systemic lupus erythematosus (SLE) .

HY-P99529

Valziflocept BAX1810; TAK-752	Fc Receptor (FcR)	Inflammation/Immunology
Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind and neutralize pathogenic IgG, thus forming a "decoy" or "scavenger" receptor that can reduce the severity of autoimmune diseases. Valziflocept can be used in studies of autoimmune diseases such as systemic lupus erythematosus (SLE) .

Cat. No.	Product Name	Type

HY-76082A

L-Pyroglutamic acid sodium	Biochemical Assay Reagents
L-Pyroglutamic acid sodium is the levo-isomer of Pyroglutamic acid. L-Pyroglutamic acid sodium is the biologically active enantiomer in humans. Pyroglutamic acid is an intermediate in glutathione metabolism. L-Pyroglutamic acid sodium can be used as a biomarker for systemic lupus erythematosus (SLE) .

Cat. No.	Product Name	Target	Research Area

HY-P3560

Edratide TV 4710	Apoptosis	Inflammation/Immunology
Edratide (TV 4710) is a synthetic peptide of 19 amino acid based on the complementarity-determining region 1 (CDR1) of a human anti-DNA antibody that expresses a major idiotype denoted 16/6 Id. Edratide reduces the rates of apoptosis (Apoptosis) and down-regulates of caspase-8 and caspase-3, up-regulates Bcl-xL. Edratide has the potential for the research of systemic lupus erythematosus (SLE) .

HY-P3507

Dalazatide ShK-186	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-P3507A

Dalazatide TFA ShK-186 TFA	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-105037A

Forigerimod TFA IPP-201101 TFA	Autophagy	Inflammation/Immunology
Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-105037

Forigerimod IPP-201101	Autophagy	Inflammation/Immunology
Forigerimod (IPP-201101) is a CD4 T-cell modulator. Forigerimod is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-P5509

C5aR1 antagonist peptide	Peptides	Others
C5aR1 antagonist peptide is a biological active peptide. (This linear peptide is derived from the C-terminus of the chemokine, complement fragment 5 anaphylatoxin (C5a). This peptide functions to inhibit C5a binding and function at human and rat C5a receptors. C5a is crucial to triggering cellular immune responses and its overexpression is involved in arthritis, Alzheimer’s disease, cystic fibrosis, systemic lupus erythematosus, and other immunoinflammatory diseases.)

Cat. No.	Product Name	Target	Research Area

HY-P99267

Rontalizumab RhuMab IFNalpha; Anti-Human IFN alpha Recombinant Antibody	Inhibitory Antibodies	Inflammation/Immunology
Rontalizumab is a humanized IgG1 monoclonal antibody targets IFN-α. Rontalizumab can be used for the research of systemic lupus erythematosus[1].

HY-P99842A

Dapirolizumab	TNF Receptor	Inflammation/Immunology
Dapirolizumab is a monoclonal antibodi against CD40 ligand. Dapirolizumab targets CD40L, blocks its interaction with CD40 receptors, and inhibits adaptive immune activation. Dapirolizumab attenuates systemic lupus erythematosus .

HY-P99219

Sifalimumab MEDI-545; MDX 1103	IFNAR	Inflammation/Immunology
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research .

HY-P99168

Anifrolumab 2 Publications Verification	IFNAR	Inflammation/Immunology
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research .

HY-P99220

Tabalumab LY2127399	TNF Receptor	Inflammation/Immunology Cancer
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .

HY-P99761

Obexelimab XmAb5871	CD19 Apoptosis	Inflammation/Immunology
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .

HY-P99315

Ruplizumab BG 9588; Anti-Human CD40L Recombinant Antibody; Hu5c8	TNF Receptor	Inflammation/Immunology
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99625

Frexalimab SAR441344; INX-021	TNF Receptor	Metabolic Disease Inflammation/Immunology
Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sj gren’s syndrome and type I diabetes research .

HY-P991313

PD-360324	c-Fms	Inflammation/Immunology
PD-360324 is a human monoclonal antibody (mAb) targeting CSF1/M-CSF. PD-360324 can be used in cutaneous lupus erythematosus, pulmonary sarcoidosis and rheumatoid arthritis research .

HY-P99893

Rozibafusp alfa AMG-570	CD28 TNF Receptor	Others
Rozibafusp alfa (AMG-570) is a humanized IgG2-κ monoclonal antibody targets ICOSL and BAFF. Prezalumab demonstrates beneficial activities on the arthritis of systemic lupus erythematosus. Prezalumab can be used for the research of sjogren's syndrome cutaneous lupus erythematosus, psoriasis and systemic lupus erythematosus (SLE) .

HY-P991272

ATR-107	Interleukin Related	Inflammation/Immunology
ATR-107 is a humanized monoclonal antibody inhibitor targeting interleukin-21 receptor (IL-21R). ATR-107 is promising for research of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus .

HY-P9990

Litifilimab BIIB059	C-type Lectin-like Receptors (CTLRs) Transmembrane Glycoprotein	Inflammation/Immunology
Litifilimab (BIIB059) is a humanized anti-BDCA2 IgG1 monoclonal antibody administered subcutaneously. Litifilimab can inhibit the production of type I interferons, cytokines and chemokines. Litifilimab can be used in the research of diseases such as systemic lupus erythematosus .

HY-P991251

QX006N	IFNAR	Inflammation/Immunology
QX006N is a humanized monoclonal antibody inhibitor targeting human interferon α/β receptor 1 (IFNAR1). QX006N is promising for research of systemic lupus erythematosus (SLE) and other IFNAR1-related autoimmune diseases .

HY-P9952

Belimumab 2 Publications Verification LymphoStat B	TNF Receptor CD20	Inflammation/Immunology Cancer
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research .

HY-P99529

Valziflocept BAX1810; TAK-752	Fc Receptor (FcR)	Inflammation/Immunology
Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind and neutralize pathogenic IgG, thus forming a "decoy" or "scavenger" receptor that can reduce the severity of autoimmune diseases. Valziflocept can be used in studies of autoimmune diseases such as systemic lupus erythematosus (SLE) .

HY-163480

PF-06835375	CXCR	Inflammation/Immunology
PF-06835375 is a humanized IgG1 antibody selective against CXCR5 expressed on B cells, Tfh cells, and circulating Tfh-like (cTfh) cells. PF-06835375 can be used for the study of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) ^[1].

HY-P99414

Prezalumab AMG 557	Transmembrane Glycoprotein Interleukin Related	Inflammation/Immunology
Prezalumab (AMG 557) is a humanized IgG2 monoclonal antibody targeting ICOSL. Prezalumab inhibits T cell activation and related immune responses by binding to ICOSL and blocking the interaction between ICOS and ICOSL. Prezalumab can be used in the research of autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .

HY-P99325

Toralizumab IDEC-131; Anti-Human CD40 ligand Recombinant Antibody	TNF Receptor	Inflammation/Immunology
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease .

HY-P990091

Riliprubart SAR 445088	Complement System	Inflammation/Immunology
Riliprubart (SAR 445088) is an anti-C1s humanized IgG4 monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a. Riliprubart can be used to study complement-mediated diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Cat. No.	Product Name	Chemical Structure

HY-B0214S2

Prednisone-d4
Prednisone-d₄ is deuterated labeled Prednisone (HY-B0214). Prednisone (Adasone) is a corticosteroid agent with anti-inflammatory and immunosuppressive effects that can be used to study diseases related to systemic lupus erythematosus .

HY-B0214S1

Prednisone-d7
Prednisone-d₇ (Dehydrocortisone-d₇) is deuterium labeled Prednisone. Prednisone (Adasone) is a corticosteroid agent with anti-inflammatory and immunosuppressive effects that can be used to study diseases related to systemic lupus erythematosus .

HY-76082S1

L-Pyroglutamic acid-13C5

L-Pyroglutamic acid- ¹³C₅ is the ¹³C labeled L-Pyroglutamic acid (HY-76082) . L-Pyroglutamic acid is the levo-isomer of Pyroglutamic acid. L-Pyroglutamic acid is the levo-isomer of Pyroglutamic acid. L-Pyroglutamic acid is the biologically active enantiomer in humans. Pyroglutamic acid is an intermediate in glutathione metabolism. L-Pyroglutamic acid can be used as a biomarker for systemic lupus erythematosus (SLE) .

HY-B0214S3

Prednisone-13C2,d2
Prednisone- ¹³C₂,d₂ (Dehydrocortisone- ¹³C₂,d₂) is ¹³C labeled Prednisone. Prednisone (Adasone) is a corticosteroid agent with anti-inflammatory and immunosuppressive effects that can be used to study diseases related to systemic lupus erythematosus .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81169A

	PD-1 Antibody(YA3401) Programmed cell death protein 1; CD279; CD279 antigen; hPD 1; hPD-1; hSLE1; PD 1; PD1; PDCD 1; PDCD1; PDCD1_HUMAN; Programmed cell death 1; Protein PD 1; Protein PD-1; SLEB2; Systemic lupus erythematosus susceptibility 2.	WB, IHC-P, ICC/IF, FC	Human
	PD-1 Antibody is an unconjugated, approximately 32 kDa, rabbit-derived, anti-PD-1 monoclonal antibody. PD-1 Antibody can be used for: WB, IHC-P, Flow-Cyt, IF/ICC expriments in human background without labeling.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-150751

ODN TTAGGG 1 Publications Verification ODN A151		CpG ODNs
ODN TTAGGG (A151), inhibitory oligonucleotide (ODN), is a TLR9, AIM2 and cGAS antagonist. ODN TTAGGG is immunosuppressive and inhibits AIM2 inflammasome activation, as well as cGAS activation, by competing with DNA. ODN TTAGGG can be used in the study of lupus erythematosus and other related autoimmune diseases. ODN TTAGGG sequence: 5'-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-3' .

HY-150751C

ODN TTAGGG sodium 1 Publications Verification ODN A151 sodium		CpG ODNs
ODN TTAGGG sodium, inhibitory oligonucleotide (ODN), is a TLR9, AIM2 and cGAS antagonist. ODN TTAGGG sodium is immunosuppressive and inhibits AIM2 inflammasome activation, as well as cGAS activation, by competing with DNA. ODN TTAGGG sodium can be used in the study of lupus erythematosus and other related autoimmune diseases. ODN TTAGGG sequence: 5'-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-3' .

HY-150740A

ODN 21595 sodium		CpG ODNs
ODN 21595 sodium is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 sodium inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 sodium reduces the expression of CD86 and HLA-DR. ODN 21595 sodium has the potential for the research of systemic lupus erythematosus (SLE) .

HY-150740

ODN 21595		CpG ODNs
ODN 21595 is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 reduces the expression of CD86 and HLA-DR. ODN 21595 has the potential for the research of systemic lupus erythematosus (SLE) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

lupus erythematosus

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products